BRIEF published on 08/08/2025 at 23:35, 1 year 2 months ago La FDA approuve le système Genio® de Nyxoah pour le traitement de l'apnée obstructive du sommeil Approbation De La FDA Nyxoah Apnée Obstructive Du Sommeil Commercialisation Aux États-Unis Système Genio
PRESS RELEASE published on 08/08/2025 at 23:30, 1 year 2 months ago Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea Nyxoah receives FDA approval for Genio System, advancing OSA treatment with bilateral stimulation and leadless technology. U.S. commercialization launched FDA Approval Nyxoah Obstructive Sleep Apnea Neuromodulation Genio System
BRIEF published on 07/28/2025 at 22:10, 1 year 3 months ago Nyxoah’s DREAM Study Data Featured in Clinical Journal Obstructive Sleep Apnea DREAM Study Clinical Outcomes Genio® System Patient Satisfaction
BRIEF published on 07/28/2025 at 22:10, 1 year 3 months ago Les données de l'étude DREAM de Nyxoah présentées dans une revue clinique Résultats Cliniques Apnée Obstructive Du Sommeil Étude DREAM Système Genio® Satisfaction Des Patients
PRESS RELEASE published on 07/28/2025 at 22:05, 1 year 3 months ago Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Nyxoah's DREAM pivotal study data on Genio system for OSA treatment published in Journal of Clinical Sleep Medicine. Study shows high patient satisfaction & improved quality of life Sleep Medicine Nyxoah Genio System DREAM Pivotal Study OSA Treatment
BRIEF published on 05/14/2025 at 07:05, 1 year 5 months ago Nyxoah Reports First Quarter 2025 Financial and Operating Results Financial Results FDA Approval Nyxoah Q1 2025 Genio System
BRIEF published on 05/14/2025 at 07:05, 1 year 5 months ago Nyxoah publie ses résultats financiers et opérationnels du premier trimestre 2025 Résultats Financiers Approbation De La FDA Nyxoah Système Genio T1 2025
PRESS RELEASE published on 05/14/2025 at 07:00, 1 year 5 months ago Nyxoah Reports First Quarter Financial and Operating Results Nyxoah reports financial and operating results for the first quarter of 2025, including progress towards FDA PMA approval for the Genio® system. Revenue €1.1 million. Cash position €63.0 million Financial Results FDA Approval Operating Highlights Nyxoah Genio® System
BRIEF published on 04/08/2025 at 07:05, 1 year 6 months ago Nyxoah informe sur le processus d'approbation du système Genio par la FDA Technologie Médicale Approbation De La FDA Nyxoah Apnée Obstructive Du Sommeil Système Genio
BRIEF published on 04/08/2025 at 07:05, 1 year 6 months ago Nyxoah Updates on FDA Approval Process for Genio System FDA Approval Medical Technology Nyxoah Obstructive Sleep Apnea Genio System
Published on 10/30/2026 at 23:35, 16 hours 8 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 16 hours 13 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 18 hours 56 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 20 hours 43 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 16 hours 54 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 21 hours 5 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 16 hours 43 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 16 hours 43 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
